Literature DB >> 17452697

A study of blood product use in patients with major trauma in Scotland: analysis of a major trauma database.

Randal J McRoberts1, D Beard, T S Walsh.   

Abstract

OBJECTIVES: (1) To define blood product requirements in patients with trauma whose underlying injuries are consistent with major blood loss; (2) to use these data to estimate the annual number of patients in Scotland who sustain significant trauma and require substantial blood product replacement; and (3) to place these data in the context of recent findings concerning the efficacy of recombinant factor VIIa in patients with major trauma.
METHODS: A retrospective case note review study was conducted for patients who presented with trauma at each of four Scottish hospitals. The four sites were selected from the 26 hospitals that were the source of data for the Scottish Trauma Audit Group (STAG) database. Collected between 1991 and 2002, STAG encompasses approximately 53 000 patients. 129 patients whose trauma codes were likely to be linked to injuries associated with major blood loss were selected. Data on the use of blood products for each patient were collected and analysed for three periods: (1) time spent in the emergency department (ED); (2) time from leaving the ED to the end of the first 24 h; and (3) time from the end of the first 24 h to 7 days. Blood product use for each period and for the entire first week of care was described for all patients and for blunt and penetrating injury subgroups. Using national population data estimates, the incidence of major trauma requiring blood transfusion was calculated for Scotland.
RESULTS: Among the patients with trauma codes predicting significant blood loss, the proportion of patients requiring any blood transfusion within the first 7 days was 53.9%. 27.4% of patients received > or =8 units of red cell concentrate (RCC) within the first 24 h of hospitalisation. By direct extrapolation, we estimated that the annual number of Scotland's patients (aged >13 years) with a significant blood transfusion requirement secondary to traumatic injury was 67. Of these, 35 patients would require > or =8 units of RCC within the first 24 h.
CONCLUSION: In summary, this study estimates that approximately 67 patients annually in Scotland, above the age of 13 years, require blood transfusion as a direct result of significant traumatic injury. Of these 67 patients, an estimated 35 patients (28 of whom had a blunt form of trauma) require > or =8 units of RCC during the first 24 h in hospital. On the basis of the current limited trial evidence, the potential benefit in using recombinant factor VIIa in such patients, in Scotland, is small-approximately seven patients per million population aged >13 years, per year.

Entities:  

Mesh:

Year:  2007        PMID: 17452697      PMCID: PMC2658474          DOI: 10.1136/emj.2006.044198

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  11 in total

1.  Prehospital trauma management: a national study of paramedic activities.

Authors:  S Sukumaran; J M Henry; D Beard; R Lawrenson; M W G Gordon; J J O'Donnell; A J Gray
Journal:  Emerg Med J       Date:  2005-01       Impact factor: 2.740

2.  Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.

Authors:  Jerrold H Levy; Abe Fingerhut; Thomas Brott; Irene H Langbakke; Elisabeth Erhardtsen; Robert J Porte
Journal:  Transfusion       Date:  2006-06       Impact factor: 3.157

3.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

Authors:  Kenneth David Boffard; Bruno Riou; Brian Warren; Philip Iau Tsau Choong; Sandro Rizoli; Rolf Rossaint; Mads Axelsen; Yoram Kluger
Journal:  J Trauma       Date:  2005-07

4.  Massive transfusion exceeding 50 units of blood products in trauma patients.

Authors:  Steven N Vaslef; Nancy W Knudsen; Patrick J Neligan; Mark W Sebastian
Journal:  J Trauma       Date:  2002-08

5.  Analysis and results of the recombinant factor VIIa extended-use registry.

Authors:  Michael Laffan; Niamh M O'Connell; David J Perry; Andrew J Hodgson; Denise O'Shaughnessy; Owen P Smith
Journal:  Blood Coagul Fibrinolysis       Date:  2003-06       Impact factor: 1.276

6.  Blood transfusion, independent of shock severity, is associated with worse outcome in trauma.

Authors:  Debra L Malone; James Dunne; J Kathleen Tracy; A Tyler Putnam; Thomas M Scalea; Lena M Napolitano
Journal:  J Trauma       Date:  2003-05

7.  [Evaluation of costs incurred for patients with multiple trauma particularly from the perspective of the hospital].

Authors:  T Schwermann; M Grotz; M Blanke; S Ruchholtz; R Lefering; J M Graf V d Schulenburg; C Krettek; H C Pape
Journal:  Unfallchirurg       Date:  2004-07       Impact factor: 1.000

8.  Is there a limit to massive blood transfusion after severe trauma?

Authors:  G C Velmahos; L Chan; M Chan; R Tatevossian; E E Cornwell; J A Asensio; T V Berne; D Demetriades
Journal:  Arch Surg       Date:  1998-09

9.  The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.

Authors:  Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Edward Abraham; Neil R MacIntyre; M Michael Shabot; Mei-Sheng Duh; Marc J Shapiro
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

10.  Recombinant activated factor VII for the treatment of life-threatening haemorrhage.

Authors:  John W Eikelboom; Robert Bird; David Blythe; Luke Coyle; Eng Gan; Michael Harvey; James Isbister; Michael Leahy; David McIlroy; Farhad Rahimpanah; Sundra Ramanthan; Simone Strasser; Chris Ward; Andrew Watts; Simon Towler; Qilong Yi
Journal:  Blood Coagul Fibrinolysis       Date:  2003-12       Impact factor: 1.276

View more
  1 in total

1.  Using qualitative research methods in biomedical innovation: the case of cultured red blood cells for transfusion.

Authors:  Catherine Lyall; Emma King
Journal:  BMC Res Notes       Date:  2016-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.